Empowering treatment decisions in NSCLC

Gold-standard testing

Mutation analysis is the go-to method for to determine the presence or absence of a driver mutation in EGFR and enables oncologists to decide whether to use an EGFR TKI for initial treatment of a patient with advanced NSCLC (3, 4). Our new therascreen EGFR Plus RGQ PCR Kit detects all currently known activating and resistance EGFR mutations and supports your treatment decision making.

Predicting sensitivity to therapy

We know that many oncogenes can play a role in NSCLC. Mutations in the EGFR gene occur in ~15% of NSCLC adenocarcinomas (rising significantly – up to 63% – in Asian populations) (2). The presence of certain EGFR mutations predicts for sensitivity to EGFR tyrosine kinase inhibitors (TKIs) and confers a more favorable prognosis (3).

Flexible, sensitive EGFR mutation testing in NSCLC

Join Scott Markland to learn about the role of EGFR in non-small cell lung cancer, including the changing mutational landscape of EGFR testing in response to treatment with targeted therapies. Then, discover how testing with the therascreen EGFR Plus RGQ PCR Kit can benefit you and your NSCLC patients.

Sensitive detection of EGFR mutations

The therascreen EGFR Plus RGQ PCR Kit is an in vitro diagnostic test to support your selection of NSCLC patients for therapy with EGFR tyrosine kinase inhibitors (TKIs), based on the detection of mutations in the EGFR gene (5).

Regular testing using liquid biopsy (plasma) samples can help to positively impact treatment outcomes, by ensuring patients get the right treatment at the right stage of their treatment journey.

Enabling precision healthcare for your patients

Our therascreen kits for solid tumor diagnostics allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Get the latest insights from oncology experts

Catch up with our solid tumor webinars wherever you are, at a time that works for you.